Sean MacKnight
Education
M.Sc., public health, and B.Sc., biochemistry, McGill University
Summary of Experience
Mr. MacKnight specializes in epidemiology and health economics and outcomes research (HEOR). He has extensive experience using health insurance claims and electronic medical record databases to retrospectively evaluate the effectiveness and safety of medications; model risk factors; and assess treatment patterns, health care resource utilization, and costs. He has conducted research in numerous therapeutic areas, including asthma, chronic obstructive pulmonary disease, bipolar disorder, migraine, atrial fibrillation, and lymphoma. His research has been presented at scientific conferences, including those of the American Thoracic Society, the International Society for Pharmacoeconomics and Outcomes Research, and the Academy of Managed Care Pharmacy. His research has been published in peer-reviewed journals such as the Journal of Affective Disorders, Cancer Medicine, The Journal of Allergy and Clinical Immunology: In Practice, and the Journal of Medical Economics.
-
Evaluating the real-world effectiveness of belimumab in patients with SLE using SLE-related laboratory values and rheumatoid arthritis-derived disease activity measures: RAPID3, swollen joint count and tender joint count
Lupus Science & Medicine, 2024
2024Germain G, Worley K, MacKnight SD, Rubin B, Bell CF, Laliberté F, Urosevic A, Duh MS, Concoff A
-
Real-world association between systemic corticosteroid exposure and complications in US patients with severe asthma
Allergy, Asthma & Clinical Immunology, 2024
2024Casale TB, Corbridge T, Germain G, Laliberté F, MacKnight SD, Boudreau J, Duh MS, Deb A
-
Impact of formulary-related pharmacy claim rejections of cariprazine on health care utilization and treatment patterns among patients with bipolar I disorder
Journal of Managed Care & Specialty Pharmacy, 2024
2024Laliberté F, Zanardo E, MacKnight SD, Urosevic A, Wade SW, Parikh M
-
The real-world health resource use and costs of misdiagnosing bipolar I disorder
Journal of Affective Disorders, 2022
2022McIntyre RS, Laliberté F, Germain G, MacKnight SD, Gillard P, Harrington A
-
Adherence and Persistence to Single-Inhaler Versus Multiple-Inhaler Triple Therapy for Asthma Management
The Journal of Allergy and Clinical Immunology: In Practice, 2022
2022Busse WW, Abbott CB, Germain G, Laliberté F, MacKnight SD, Jung Y, Duh MS, Averell CM
-
Benefit of Prompt versus Delayed Use of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Following a COPD Exacerbation
International Journal of Chronic Obstructive Pulmonary Disease, 2022
2022Mannino D, Bogart M, Germain G, Huang SP, Ismaila AS, Laliberté F, Jung Y, MacKnight SD, Stiegler MA, Duh MS
-
Impact of adherence to treatment with inhaled corticosteroids/long-acting β-agonists on asthma outcomes in the United States
Therapeutic Advances in Respiratory Disease, 2022
2022Averell CM, Laliberté F, Germain G, Duh MS, Rousculp MD, MacKnight SD, Slade DJ
-
Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA
Targeted Oncology, 2021
2021Laliberté F, Raut M, Yang X, Germain G, Nahar A, Desai KD, MacKnight SD, Sen SS, Duh MS
-
Umeclidinium/Vilanterol Compared with Fluticasone Propionate/Salmeterol, Budesonide/Formoterol, and Tiotropium as Initial Maintenance Therapy in Patients with COPD Who Have High Costs and Comorbidities
International Journal of Chronic Obstructive Pulmonary Disease, 2021
2021Kalhan R, Slade D, Ray R, Moretz C, Germain G, Laliberté F, Shen Q, Duh MS, MacKnight SD, Hahn B
-
Cancer associated thrombosis and mortality in patients with cancer stratified by khorana score risk levels
Cancer Medicine, 2020
2020Khorana AA, Kuderer NM, McCrae K, Milentijevic D, Germain G, Laliberté F, MacKnight SD, Lefebvre P, Lyman GH, Streiff MB
-
December 4, 2024
-
October 19, 2023
-
March 2, 2023
-
October 15, 2021